Skip to search formSkip to main contentSkip to account menu

trebananib

Known as: trenananib 
An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

AMG 386

Broader (3)

Angiogenesis InhibitorsPharmacologic SubstanceRecombinant Fusion Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
2018
2018
Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
Background: Pathological complete response (pCR) is accepted by FDA as a surrogate endpoint for accelerated approval of targeted… 
2016
2016
Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials
Abstract Objectives: To investigate the effects of angiogenesis inhibitors in the treatment of patients with advanced or… 
2015
2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
SummaryBackground Trebananib is an anti-angiogenic peptibody under investigation in patients with advanced cancer. This study… 
2015
2015
Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.
3533 Background: VEGF-A and Ang play complementary roles in regulation of blood vessel growth, maturation and function. Hence we… 
Review
2015
Review
2015
Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Review
2015
Review
2015
Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies
AbstractPurpose To provide the first evaluation of pharmacokinetic (PK) drug–drug interactions (DDIs) between trebananib and… 
2014
2014
Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia.
7082 Background: Angiopoietins (Ang-1/2), pro-angiogenic factors binding to the Tie2 receptor on endothelial cells, have been… 
2014
2014
A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer.
218 Background: Trebananib is an angiopoietin1/2 antagonist peptibody. Androgens stimulate expression of VEGF via activation of… 
2014
2014
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)